Related Experiment Video
Updated: Jul 31, 2026

11:25
Quantitative Analysis of Protein Expression to Study Lineage Specification in Mouse Preimplantation Embryos
Published on: February 22, 2016
10.9K
Towards Automation in IVF: Pre-Clinical Validation of a Deep Learning-Based Embryo Grading System during PGT-A
Danilo Cimadomo1, Viviana Chiappetta1, Federica Innocenti1
1Clinica Valle Giulia, GeneraLife IVF, Via De Notaris 2B, 00197 Rome, Italy.
Journal of Clinical Medicine
|March 11, 2023
Summary
Artificial intelligence, like iDAScore v1.0, can objectively rank blastocysts for improved embryo selection. This deep-learning model shows promise in complementing human evaluation, though clinical trials are needed.
Area of Science:
- Reproductive medicine
- Embryology
- Artificial intelligence in healthcare
Background:
- Preimplantation genetic testing for aneuploidies (PGT-A) is effective but resource-intensive.
- Current embryo selection relies on morphological evaluation, which lacks reproducibility.
- There is a need for objective, non-invasive embryo assessment tools.
Purpose of the Study:
- To externally validate the iDAScore v1.0, a deep-learning model for blastocyst assessment.
- To evaluate the association of iDAScore v1.0 with embryo morphology and competence.
- To compare the objectivity and reproducibility of iDAScore v1.0 with human embryologists' evaluations.
Main Methods:
- Retrospective analysis of 3604 blastocysts from 1232 cycles.
- External validation of the iDAScore v1.0 deep-learning model.
- Assessment of iDAScore v1.0's association with euploidy and live-birth prediction.
Main Results:
- iDAScore v1.0 showed significant association with embryo morphology and competence.
- Area under the curve (AUC) for euploidy and live-birth prediction were 0.60 and 0.66, respectively.
- iDAScore v1.0 demonstrated objectivity and reproducibility, unlike human evaluations.
Conclusions:
- iDAScore v1.0 can objectively support embryologists' blastocyst evaluations.
- The model could identify euploid embryos as top quality in 63% of simulated cases.
- Further randomized controlled trials are necessary to determine the clinical utility of iDAScore v1.0.

